Business Wire

CA-RECVUE

14.1.2021 15:02:34 CET | Business Wire | Press release

Share
RecVue Raises $13M Series A to Automate Order-to-Cash Process for Enterprises and Bridge the Gap between CRM and ERP systems

RecVue, provider of Order Lifecycle Management (OLM) solutions designed to modernize the complex order-to-cash (O2C) processes for enterprises, has raised $13 million in a Series A round. Cota Capital led the round, in which Epic Ventures and Long Light Capital also participated. RecVue will use the funding to expand its engineering, go-to-market efforts and international presence.

“We offer the industry’s only suite of OLM solutions that are purpose-built to address the growing gap between front- and back-office business processes,” said Nishant Nair, founder and CEO of RecVue. “This fundraising round provides a dynamic foundation for rapid growth in our go-to-market operations as well as allowing us to quickly add new capabilities to our OLM suite of applications to scale to the $150 billion revenue under management target.”

Bobby Yazdani, managing partner for Cota Capital, added “Since its launch, RecVue’s technology has been transforming the order-to-cash process, helping customers innovate and operate new business models and manage complex revenue streams at unprecedented scale, speed and efficiency. The RecVue leadership team has crafted a powerful strategic plan that has them poised to transform order-to-cash needs of hundreds of large enterprises and process billions of transactions over the next several years.”

The “middle office” is the command center for the enterprise, encompassing all the business functions that sit between the traditional front-and-back systems -- from initial engagement to managing relationships and complex order-to-cash processes such as billing, revenue management and channel partner compensation. The middle office presents a largely untapped opportunity to harness revenue potential by leveraging back-office data to influence front-office business decisions.

Yet, many organizations today are experiencing a growing “middle office” gap between their customer-facing front-office CRM systems and transaction-heavy, back-office ERP systems. Faced with data silos, fragmented and often manual processes, and custom-built applications and spreadsheets, many companies are forced to do complicated data integrations to make CRM and ERP systems work together.

RecVue addresses the middle office gap more efficiently and effectively by fully automating the complex order-to-cash processes for billing, revenue, accruals management and channel partner payments. Additionally, RecVue provides robust analytics and reporting. Customers using RecVue’s unified approach have benefited by closing their books earlier, reducing their compliance risk, and significantly lowering their total cost and overhead.

“We’ve been able to significantly reduce the cost and complexity of our revenue operations using RecVue’s OLM suite of applications,” said Philipp Lustenberger, CFO, General Assembly, part of Adecco group. “Automating, streamlining, and optimizing our order-to-cash process has helped our finance and operations teams focus more on the strategic challenges that we face.”

Mark Thomason, IDC’s Research Director for Digital Business Models and Monetization said, “The COVID-19 pandemic has accelerated the trend toward recurring business models and selling over new digital channels, including multi-partner marketplaces. This has increased monetization complexity and the need to scale quickly. Future-focused companies are adopting agile monetization systems such as RecVue’s OLM suite to easily implement complex recurring business models, automate the order-to-cash process, and easily manage partner settlement to enable the goal of continuous accounting close.”

About RecVue

RecVue empowers enterprises to modernize their billing and revenue operations at speed and scale by harnessing previously untapped revenue potential and leveraging front-office CRM data and back-office ERP systems to influence business decisions. Trusted by the world’s leading companies in business services, transportation and logistics, financial services, media and technology, including Hertz, General Assembly, ACI Worldwide, and Textainer, RecVue’s suite of purpose-built cloud applications enable enterprises to expand recurring revenue and automate complex order-to-cash (O2C) processes. For more information, visit www.recvue.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 13:30:00 CEST | Press release

Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily pretreated population where durable long-term survival is rarely reported17% of patients alive and off all systemic anticancer therapy at last follow-upExtended safety follow-up showed no new safety signals, no treatment-related deaths, and 98% resolution of immune-mediated diarrhea/colitis Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (E

LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 11:12:00 CEST | Press release

New assessment and risk assurance framework helps enterprises gain unified visibility, prioritise remediation and scale AI securely LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to

Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release

Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri

HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release

A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye